A planned preclinical study will compare MicronJet’s suprachoroidal administration with existing methods, testing whether it can place exosome formulations consistently near the retina and optic nerve.
Gallant is betting the future of veterinary regenerative medicine lies in scalable, well-characterized cell therapies. By sourcing mesenchymal stem cells from uterine tissue collected during routine spays, it has built an off-the-shelf platform with consistent, high-yield cells and FDA-aligned manufacturing, with a potential first FDA…
The partnership will support clinical and future commercial supply of RION’s exosome therapies for tissue repair and regenerative medicine.
Klotho Neurosciences expands into cellular reprogramming with a planned Turn Biotechnologies acquisition and significant pharma partnership.
Independent analysis finds NurExone’s exosomes deliver enhanced regenerative signals, showing promise for nerve repair and tissue healing applications.